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Replication protein A (RPA) is the main eukaryotic single-strand (ss) DNA-binding protein involved in DNA replication and
repair. We have identiﬁed and developed two classes of small molecule inhibitors (SMIs) that show in vitro inhibition of
the RPA-DNA interaction. We present further characterization of these SMIs with respect to their target binding, mechanism
of action, and speciﬁcity. Both reversible and irreversible modes of inhibition are observed for the diﬀerent classes of SMIs
with one class found to speciﬁcally interact with DNA-binding domains A and B (DBD-A/B) of RPA. In comparison with
other oligonucleotide/oligosaccharide binding-fold (OB-fold) containing ssDNA-binding proteins, one class of SMIs displayed
speciﬁcity for the RPA protein. Together these data demonstrate that the speciﬁc targeting of a protein-DNA interaction can be
exploited towards interrogating the cellular activity of RPA as well as increasing the eﬃcacy of DNA-damaging chemotherapeutics
used in cancer treatment.
1.Introduction
Replication protein A (RPA) is an essential protein involved
innumerousDNAmetabolicpathwaysincludingreplication,
repair, and recombination. RPA’s activity in these pathways
is in part a function of its single-stranded DNA (ssDNA)
binding activity. RPA is a heterotrimeric protein comprised
of 70-, 34-, and 14-kDa subunits [1] and binds to DNA
through interactions with a series of OB-folds that display a
high aﬃnity for ssDNA [2]. OB-folds are found in numerous
proteins, speciﬁcally those that perform their function
through the interaction with single-stranded nucleic acid
structures including tRNA synthetases, telomeres, and repli-
cation and repair intermediates [3]. The human telomeric
DNA-binding proteins, POT1 and TPP1, both use OB-folds
to recognize and bind the 3  ssDNA overhang of telomeres
[4, 5]. The breast cancer susceptibility protein, BRCA2,
has three OB-folds that confer binding to ssDNA, which
stimulates RAD51-mediated recombination [6]. The OB-
fold, also referred to as a Greek key motif [3], consists of
two three-stranded antiparallel β-sheets in which one strand
is shared between them, forming a β-barrel structure. An
α-helix is typically located between strands 3 and 4, which
packsagainstthebottomoftheβ-barrel[7].TheRPA70-kDa
subunitcontainsfourputativeOB-folds,twoofwhich(Aand
B) comprise the central DNA binding domain (DBD-A/B),
whichcontributesthemajorityofthessDNAbindingactivity
of the heterotrimeric protein. While other DNA binding
domains within RPA include zinc ribbons and helix-turn-
helix motifs [8], the OB-folds of DBD-A/B possess aromatic
amino acid residues (F238 and F269 in DBD-A and W361
and F386 in DBD-B) that provide critical base-stacking2 Journal of Nucleic Acids
interactions [9]. A recombinant construct containing the
DBD-A/B of RPA has been expressed, puriﬁed, and shown
to be suﬃcient to bind DNA [9].
The importance of RPA in DNA replication has been
demonstrated by genetic studies in yeast [10], genetic
knockdown studies in human cells [11] and more recently
in chemical genomic studies with an SMI of RPA [12]. RPA
plays multiple roles in DNA replication including assembly
of prereplication complexes and stabilization of ssDNA
following helicase-catalyzed unwinding [13]. Moreover, very
recentdatademonstratingthatRPAcanunwindduplexDNA
has led to a model where RPA may help in maintaining
double-stranded DNA stability throughout replication [14].
Inhibition of any one of these steps is likely to have
deleterious eﬀects on DNA replication and ultimately cell
viability.
RPA inhibition with a recently identiﬁed SMI of RPA,
TDRL-505, has been demonstrated to synergize with cis-
platin in a human lung cancer cell model [12]. This eﬀect is
likely to be a function of alterations in DNA repair, specif-
ically nucleotide excision repair (NER), though eﬀects on
homologous recombination cannot be ruled out. Cisplatin
[cis-diamminedichloroplatinum (II)) is commonly used as
a chemotherapeutic drug in cancer treatment that forms
cytotoxic intra- and interstrand DNA-cisplatin adducts.
DNA-cisplatin adducts are repaired mainly through the NER
pathway, and RPA has been shown to preferentially bind
to duplex cisplatin-damaged DNA compared to undamaged
DNA through the development of ssDNA [15–17]. RPA is
also responsible for the recognition of interstrand cross-links
caused by cisplatin treatment [17, 18]. Cisplatin resistant
cancers have been linked to enhanced DNA repair, and thus
the ability to impact DNA repair eﬃciency via modulation
of RPA’s DNA-binding activity is of potential clinical use
to treat cancer in conjunction with platinum agents [19].
Etoposide, a common chemotherapeutic drug that induces
replication fork stalling by inhibiting topoisomerase II, was
also demonstrated to synergize with the RPA SMI TDRL-
505 [12]. This synergistic activity is predicted to increase
the toxic eﬀects exerted by etoposide both in the context
o fD N Ar e p l i c a t i o na n dr e p a i r .R P A ’ sr o l ei nh o m o l o g o u s
recombination may be mediating this eﬀect where DNA
double-strand breaks are processed to generate a 3  ssDNA
overhang to which RPA binds to help catalyze RAD51-
dependent strand exchange [20]. In Saccharomyces cerevisiae,
mutations within the DNA binding domain and protein-
protein interaction regions of ScRPA lead to highly decreased
meiotic recombination [21].
To further investigate the mechanisms of small molecule
inhibition of RPA, we have analyzed the in vitro activity of a
series of SMIs and their interactions with various RPA con-
structs. We assessed binding and interaction with full-length
heterotrimeric RPA and a construct comprised of just DBD-
A/B. The data presented suggest diﬀerent modes of binding
and interactions between the various classes of compounds
and RPA, indicating that they potentially target diﬀerent
OB-folds or diﬀerent regions of the protein structure. We
also present data demonstrating that one class of SMIs does
appear to have limited speciﬁcity; however another class of
SMIs is highly speciﬁc for the RPA protein-DNA interaction
and does not inhibit the interaction between ssDNA and
other OB-fold-containing proteins.
2.MaterialsandMethods
2.1. Materials. Phosphocellulose matrix was obtained from
Sigma. Radiolabeled nucleotides were purchased from
Perkin-Elmer Life Science (Boston, MA). All oligonucleotide
substrates were purchased from Integrated DNA Technology
(Coralville, IA) and gel puriﬁed by 12% polyacrylamide, 7M
urea preparative denaturing gel electrophoresis. The 3Pc3
sequence is 5 -GGA GAC CGA AGA GGA AAA GAA GGA
GAG AGG-3 , the 34-mer is 5 -CTA GAA AGG GGG AAG
AAA GGG AAG AGG CCA GAG A-3 , and the 15-mer is 5 -
GGT TAC GGT TAC CCC-3 .
2.2. Small Molecule Inhibitors. TDRL-505 was obtained from
Exclusive Chemistry (Obninsk, Russia) and CheSS19 was
prepared as described in [22]. (+/−) isobornyl haloesters
were prepared by the following general procedure. Brieﬂy,
to an ice-cooled solution of (+/−)-isoborneol (1.00g,
6.48mmol) in dry CH2Cl2 (25mL) in a Schlenk tube under
N2 wasaddeddicyclohexylcarbodiimide(1.60g,7.76mmol),
followed by the corresponding haloacid (7.15mmol) and
4-dimethylaminopyridine (77mg, 0.63mmol). The clear
colorless solution was stirred 18–24 hours at which time
TLC analysis indicated complete consumption of isoborneol
(Rf 0.26, 9:1 hexanes/EtOAc), and precipitates of dicyclo-
hexylurea were evident. Diethyl ether (25mL) was added,
precipitating the bulk of the dicyclohexylurea. The mixture
wasﬁlteredand theﬁltercakewashedwithether (2×25mL).
The ﬁltrate which had developed additional precipitate was
reﬁltered and the solvent removed by rotary evaporation.
Kugelrohrdistillationoftheresidueaﬀordedthehaloestersas
colorless oils of greater than 90% purity. Details concerning
the synthesis and chemical characterization of MCI13E and
MCI13F are presented in Supplementary Material available
online at doi:10.4061/2010/304035.
2.3. Protein Expression and Puriﬁcation
RPA. Human full-length, untagged heterotrimeric RPA
(RPA) was puriﬁed as previously described in [17].
DBD-A/B. The sequence encoding the RPA p70 DNA-
binding domains A and B was subcloned from the
hrRPA plasmid (provided by Dr. Marc Wold, University
of Iowa) into the pET15b (Novagen) vector, and the
protein was expressed in BL21(DE3) cells (Stratagene) as
previously described in [9]. Brieﬂy, cells were grown to an
OD600 of 0.8, induced with 0.5mM isopropyl-1-thio-β-D-
galactopyranoside (IPTG) at 37◦C for 2-3 hours. Small-scale
DBD-A/Bpreparationswereobtainedfrom1Lcultures,and,
followinginduction,cellswereharvestedbycentrifugationat
700 × gf o r3 0m i n u t e sa t4 ◦C. The pellets were suspended in
Buﬀer A (20mM Tris, pH 7.5, 10% glycerol, 500mM NaCl,Journal of Nucleic Acids 3
10mM β-mercaptoethanol (BME), and 1μg/mL phenyl-
methanesulfonyl ﬂuoride (PMSF), leupeptin, and pepstatin)
at 1mL/gram of cells. The cells were lysed by sonication and
insoluble material sedimented at 15,000 × gf o r3 0m i n u t e s
at 4◦C. The supernatant was then loaded onto a 10mL phos-
phocellulose column, equilibrated with Buﬀer A, and the
ﬂow-through material collected. Imidazole was added to the
ﬂow-through to a ﬁnal concentration of 5mM, which was
then loaded onto a 2mL nickel-NTA-agarose column. The
column was then washed with Buﬀer A containing 50mM
imidazole after which protein was eluted from the column
using a gradient from 50–500mM imidazole. Fractions were
analyzed for protein content using Bradford and SDS-PAGE
analysis in addition to assessment of DNA binding activity
as determined by anisotropy. Fractions containing the DBD-
A/B protein were pooled and dialyzed overnight in Buﬀer B
(1mM HEPES, pH 7.2, 10mM dithiothreitol (DTT), 50mM
NaCl, and 1 μg/mL PMSF, pepstatin, and leupeptin) and
aliquots stored at −80◦C.
2.4. Fluorescence Polarization. Fluorescence polarization
experiments were preformed as previously described in
[23]. Reactions contained 20nM F-dT12, and increasing
concentrations of RPA and DBD-A/B as indicated in the
ﬁgure legends. SMIs were diluted in H1 buﬀer (10mM
HEPES, pH 7.2, 1mM DTT, 0.01% NP-40, and 100mM
NaCl), and the ﬁnal DMSO concentration was kept below
1%.
2.5. Electrophoretic Mobility Shift Assay (EMSA)
RPA and DBD-A/B Binding. EMSAs were performed as
previously described in [16] using a purine rich ssDNA
substrate (3Pc3). Brieﬂy, reactions contained 12.5nM 5 -
[32P]-labeled 3Pc3 ssDNA and the indicated concentrations
of RPA or DBD-A/B. Protein was preincubated with the
indicated concentration of SMI for 30 minutes at 37◦C. DNA
was then added and reactions incubated for additional 5
minutes at room temperature in a ﬁnal reaction volume
of 40μL .R e a c t i o n sw e r et h e nr e s o l v e do na6 %n a t i v e
polyacrylamide gel and electrophoresed at 170 volts for 1
hour. Gels were dried and quantiﬁed via phosphorimager
analysis and ImageQuant software (Molecular Dynamics).
E. coli SSB Binding Assay. These EMSAs were performed
similarly to those for the RPA constructs, with the following
exceptions. Reactions contained 25nM of 5 -[32P]-labeled
3Pc3 ssDNA and 3.3nM (assuming homotetramer forma-
t i o n )S S Bp r o t e i n( E n z y m a t i c s ,B e v e r l y ,M A ) .R e a c t i o n s
(20μL) were carried out in 20mM HEPES, pH 7.5, 1mM
DTT, 0.01% NP-40, 100mM NaCl and resolved by 6% native
polyacrylamidegelelectrophoresisat25mAfor2hours.Gels
were dried and quantiﬁed via phosphorimager analysis as
described above.
Schizosaccharomyces pombe Pot1(DBD) Binding Assay.
E M S A sw e r ep e r f o r m e da sd e s c r i b e da b o v ef o rEcSSB.
Reactions contained 25nM of 5 -[32P]-labeled 15-mer
ssDNA and 20nM Pot1(DBD) protein (generously provided
by Dr. Deborah Wuttke, University of Colorado, Boulder).
Reactions (20μL) were carried out in 20mM HEPES, pH
7.5, 1mM DTT, 0.01% NP-40, 100mM NaCl, at room
temperature, and resolved by 6% native polyacrylamide gel
electrophoresis at 25mA for 2 hours. Gels were dried and
quantiﬁed via phosphorimager analysis as described above.
2.6. Analysis of Reversible Inhibition. To assess the reversibil-
ity of select SMIs, the indicated SMI was preincubated with
RPA or the DBD-A/B construct for 30 minutes at room tem-
perature. The resulting solution was dialyzed versus 500mL
H1 buﬀer at 4◦C using 0.5ml, 12,000 molecular weight
cut-oﬀ dialysis cassettes (Pierce). The resulting protein
was recovered and concentration determined by Bradford
analysis. Analysis of DNA binding activity was performed
either by EMSA or FP. In each series of experiments, there
was no loss of DNA binding activity in vehicle control-
treated protein.
3. Results
3.1. TDRL-505 Targets the Central OB-Folds of RPA. Pre-
vious work from our laboratory has identiﬁed two classes
of RPA SMIs [12, 22, 24]. The ﬁrst class of SMIs was
identiﬁed from screening and analysis of structure activity
relationships (SARs) of the ChemDiv library [12]. From this
analysis, TDRL-505 was identiﬁed and contains a substituted
dihydropyrazole with a 4-oxo-butanoic acid at N1, a bro-
mophenyl substituentatC3, and2-chloro7-ethoxyquinoline
at C5 (Figure 1(a)). Previous in vitro analysis suggested that
thisSMIwaspotentiallyinteractingwiththecentralOB-folds
found in RPA p70, DBD-A/B, as it was capable of blocking
RPA binding to a 12-base ssDNA [12]. RPA binding to this
short of DNA substrate is primarily through the DBD-A/B
domain. In addition, molecular modeling analysis revealed
a thermodynamically favorable interaction between TDRL-
505 and this domain [12]. DBD-A/B extends from amino
acids 181–432. It has been puriﬁed and retains DNA binding
activity, albeit at approximately 5% of that observed for
the full-length heterotrimer [25]. A similar construct of this
region, containing amino acids 181–422, was crystallized
in complex with a (dC)8 DNA substrate and the structure
solved in addition to a DNA-free structure of the 181–432
amino acid region [26, 27]. In order to examine the eﬀect
of TDRL-505 on the DBD-A/B region alone, we subcloned
aminoacids181–432ofhumanRPAp70.TheDBD-A/Bcon-
struct was overexpressed and puriﬁed to near homogeneity,
via metal aﬃnity chromatography, as determined by SDS-
PAGE (Figure 2(a)). DNA-binding activity was assessed by
EMSA and 125nM DBD-A/B selected for analysis, which
represented approximately 50% DNA binding of the 34-base
DNA substrate (data not shown). Increasing concentrations
ofTDRL-505resultedinaconcentration-dependentdecrease
in DNA binding activity as assessed by EMSA (Figure 2(b)).
Quantiﬁcation of the results demonstrates a half-maximal
inhibition of approximately 40μM( Figure 2(c)), about twice
that observed for the intact heterotrimer [12]. These data4 Journal of Nucleic Acids
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Figure 1: Chemical structure of RPA small molecule inhibitors. (a) TDRL-505; (b) CheSS19; (c) MCI13E; (d) MCI13F.
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Figure 2: TDRL-505 inhibits RPA DBD-A/B-DNA interactions. (a) SDS-PAGE analysis of puriﬁed RPA DBD-A/B. DBD-A/B was puriﬁed
a sd e s c r i b e di n“ Section 2” and analyzed by electrophoresis on a 12% NuPAGE Bis-Tris Gel. The gel was stained with Coomassie blue.
(b) EMSA analysis of TDRL-505 inhibition of DBD-A/B DNA binding activity. Assays were performed as described in “Section 2” with
increasing concentrations of TDRL-505 from 10–100μM in reactions with 12.5nM DNA and 125nM DBD-A/B. Products were analyzed
by nondenaturing gel electrophoresis, dried, and imaged by phosphorimager analysis. The arrow indicates the position of the free DNA
and the bracket the position of the bound DBD-A/B-DNA complex. (c) Quantiﬁcation of EMSA binding data from Panel (b). The signal
representing the RPA-bound and free fractions of DNA was quantiﬁed using ImageQuant software, and values represent the mean and SD
of triplicate determinations.
support a model whereby TDRL-505 inhibits RPA’s DNA
binding activity via blocking the protein-DNA interactions
at the central OB-folds in RPA p70.
3.2. CheSS19 Inhibits Both WT RPA and RPA AB Region
Interactions with DNA. The second class of SMIs we iden-
tiﬁed contain a bicyclic-isobornyl ester which was initially
identiﬁed as a hit in a screen of the NCI diversity set and
analogsidentiﬁedinasubsequentscreenoftheNCIdevelop-
mental therapeutics general library [24]. Initial SAR analysis
indicated that variation in the bridging structure had mini-
mal eﬀects on RPA inhibitory activity while creating reactive
anhydrides greatly increased activity [22]. To ascertain if
thetricyclicanhydride,CheSS19(Figure 1(b)),alsoinhibited
DNA binding via an interaction with the central DBD-A/B,
we compared its inhibitory activity towards the DBD-A/B
construct and full-length heterotrimeric RPA using EMSAJournal of Nucleic Acids 5
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Figure 3: Irreversible inhibition of RPA DBD-A/B-DNA-binding activity by CheSS19. (a) EMSA analysis of CheSS19 inhibition of RPA
DBD-A/B. Assays were performed as described in the legend to Figure 2. Reactions contained 12.5mM DNA, 50nM DBD-A/B and 0, 25,
50, 100 and 200μM CheSS19 (Lanes, 2-6, resp.) (b) CheSS19 inhibition of full-length heterotrimeric RPA as assessed by EMSA. Reactions
were identical to those in panel (a) except contained 25nM full-length RPA. (c) Quantiﬁcation of the binding data presented in panels (a)
and (b). (d) Fluorescence polarization analysis of CheSS19 inactivated RPA DBD-A/B. RPA DBD-A/B was preincubated with vehicle (1%
DMSO) or CheSS19 (1pmol in 1% DMSO) for 30 minutes at 37◦C. Following incubation, the reaction mix was dialyzed versus H1 buﬀer
overnight at 4◦C. The protein was recovered, and DNA-binding activity measured by FP analysis of binding to an F-dT12 substrate was
performed as described in “Section 2”. Bar 1: DNA control, Bar 2: control vehicle-treated DBD-A/B, and Bar 3: CheSS19-treated DBD-A/B.
Control vehicle did not show inhibition of binding before dialysis similarly to Figure 5 Lane 3. The data represent the mean and range of two
independent experiments.
analysis. The results demonstrate that CheSS19 inhibits the
DNAbinding activityoftheDBD-A/Bconstructwithsimilar
potency to the heterotrimeric RPA preparation (Figures
3(a)–3(c)). Our prior observation that CheSS19 irreversibly
inhibited full-length RPA prompted us to examine its
interaction with the smaller DBD-A/B construct to reﬁne
where it covalently binds [22]. In this experiment, DBD-
A/B was incubated with CheSS19 and then the reaction mix
dialyzedovernighttoremovedissociableinhibitor.Following
dialysis,theproteinwasassessedforbindinginaﬂuorescence
polarization assay. Data demonstrates that dialyzed DBD-
A/B that had been preincubated with CheSS19 was able
to inhibit DBD-A/B DNA-binding activity as compared to
protein incubated with DMSO vehicle (Figure 3(d)). These
results are consistent with CheSS19 inhibiting DBD-A/B in
an irreversible manner.6 Journal of Nucleic Acids
3.3. Analysis of Isobornyl Haloesters. While the anhydride
groups in the active CheSS series are eﬀective at inhibiting
RPA, no cellular activity was observed following treatment
with this series of compounds (data not shown). This is
potentially a result of the highly reactive anhydride non-
speciﬁcally bonding with other components or hydrolyzing
to an inactive dicarboxylic acid prior to encountering RPA
in the cell nucleus. We therefore employed a less reactive
substituent to assess in vitro inhibition and analyzed a
series of haloester derivatives of Isobornyl. Synthesis and
analysis with the bromo- and iodoesters MCI13E and F,
respectively (Figures 1(c) and 1(d)), revealed inhibition of
the full-length heterotrimer RPA in EMSA analysis with the
iodo-containing compound (MCI13F) being slightly more
eﬀective (Figure 4(a)). The isobornyl haloesters, MCI13E
and MCI13F, had calculated IC50 of 16.1 ± 2.8μMa n d
10.1 ± 1.0μM, respectively. Interestingly, when we assessed
inhibition of DBD-A/B, neither MCI13E nor MCI13F com-
pounds inhibited DNA binding of this protein construct
(Figure 4(b)). Due to lack of inhibition, the IC50’s for the
inhibition of the DBD-A/B with the isobornyl haloesters
were not calculable. Considering the diﬀerential inhibition
observed between the anhydride and haloesters with respect
to speciﬁcity, we sought to determine if the isobornyl
haloesters inhibited full-length RPA in an irreversible fash-
ion.Full-lengthRPAwasmixedwithMCI13Eorvehiclecon-
trol, and then the reaction mixture was dialyzed overnight.
Analysis of the resulting protein-DNA complex (Figure 5,
lanes 5 and 6) showed that, in reactions where RPA was incu-
bated with MCI13E, inhibition was not reversed by dialysis
as would be expected from a reversible inhibitor. In fact,
the degree of inhibition was similar to that observed for the
MCI13E treated RPA before dialysis (Figure 5,l a n e s3a n d4 ) .
These results indicate a mode of MCI13E inhibition of RPA
that involved a covalent adduct between the MCI13E and
RPA. These data suggest that the diﬀerent chemical reactivity
of the isobornyl haloester derivatives alkylate RPA in a dif-
ferent way that likely does not include the DBD-A/B region.
Where anhydrides preferentially react with amine residues
or hydrolyze in the aqueous medium, alkyl halides are
more reactive with sulfur nucleophiles such as Cys residues
or hydrogen-bonded OH groups such as Ser/Thr/Tyr. The
isobornyl bromoester has been used previously for labeling
cysteines. [28]. Furthermore, analysis of cellular activity
revelsthat,unliketheisobornylhaloesters,thetricyclicanhy-
dride does not display any cellular activity (data not shown).
3.4. SMI Speciﬁcity. To determine the speciﬁcity of the
TDRL-505, CheSS19, and MCI13E/F compounds, we exam-
ined their eﬀects on two ssDNA-binding proteins which
use OB-folds for recognition and binding of ssDNA, E.
coli SSB [3], and the Schizosaccharomyces pombe Pot1(DBD)
domain [29]. The EcSSB protein is a non-sequence-speciﬁc
ssDNA binding protein, whereas the SpPot1(DBD) protein
is a telomere-speciﬁc, ssDNA binding protein. In these
experiments, protein was preincubated with the SMIs, as
was done for the RPA experiments, prior to addition
of radiolabeled ssDNA to the reactions. TDRL-505 was
shown to be ineﬀective in blocking EcSSB binding to a
ssDNA substrate (Figures 6(a) and 6(b)). While there is a
slight decrease (∼20%) in binding observed at the highest
concentration of TDRL-505 tested (100μM), this is minimal
compared to the nearly 90% inhibition observed for RPA
[12] and the RPA DBD-A/B (Figure 2). Similarly, EcSSB
binding was unaﬀected by CheSS19 and the MCI13E and
MCI13F compounds (Figures 6(d) and 6(e)). In all cases,
the IC50 of the compounds examined in relation to EcSSB
binding is greater than 100μM.
To further validate the speciﬁcity of TDRL-505, we
examined its inﬂuence on the SpPot1(DBD) construct. The
mode of ssDNA binding by SpPot1(DBD) is quite diﬀerent
compared to that of the hRPA protein; however, they both
contain ssDNA-binding domains, which are responsible for
the majority of the observed DNA-binding activity of the
full-length proteins. The SpPot1(DBD) protein was found
to be inhibited by TDRL-505 (Figure 7)w i t ha nI C 50
of 15.7 ± 1.6μM. Together, these data demonstrate that
while the RPA SMIs, CheSS19, and MCI13E/F inhibit the
interactionofRPAwithssDNA,TDRL-505compoundseems
to inhibit eukaryotic ssDNA-binding OB-fold interactions as
demonstrated with two diﬀerent protein-ssDNA complexes.
4. Discussion
The six OB-folds distributed throughout three subunits of
RPA have been implicated in numerous aspects of DNA
metabolism via RPA DNA binding as well as interactions
with other proteins [11, 25]. Inhibition of DNA binding
activitybytargetingtheOB-foldswithSMIshasthepotential
to provide a separation of function and elucidate the con-
tribution of the various domains in the numerous pathways
in which RPA participates. Thus, targeting a particular OB-
fold or other interaction domain may allow for pathway-
speciﬁc targeting of RPA. For instance, one could inhibit
RPA’s activity in nucleotide excision repair (NER) and
not in replication, which would present clinical utility in
cancer treatment to allow synergy with DNA damaging
chemotherapeutic agents while potentially limiting toxicity.
IthasbeensuggestedthattheOB-foldsbeyondtheDBD-A/B
region contribute to full-length RPA’s ssDNA interaction,
which stems from the observation that while DBD-A/B can
accommodate a (dC)8 DNA substrate, variations in binding
are observed dependent on DNA sequence length [1]. Our
observation that TDRL-505 can inhibit the DBD-A/B region
of RPA p70 from binding to ssDNA supports our previously
published molecular modeling data, in which energetically
favorable binding was observed within DBD-A and DBD-B
as well as the interdomain region [12].
We have further demonstrated that, while not an
RPA-speciﬁc inhibitor, TDRL-505 displays speciﬁcity for
eukaryotic ssDNA binding activity of OB-fold containing
proteins as no signiﬁcant inhibition of the related ssDNA
binding protein, EcSSB, was observed. Although the EcSSB
and SpPot1(DBD) proteins contain OB-folds, and in this
regard, are structurally related to full-length RPA p70 and
the DBD-A/B, the mechanism of ssDNA binding by these
proteins is very diﬀerent. As shown in Figure 8(a), theJournal of Nucleic Acids 7
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Figure 4: Inhibition of full-length heterotrimeric RPA but not DBD-A/B-DNA-binding activity by the MCI13 series of bicyclic isoborneol
haloesters. The control used is a distillate of the reaction components of the synthesis of the MCI13 compounds diluted in equal
concentration of DMSO as the MCI13, inhibitors. (a) Increasing concentrations of control compound, MCI13E, or MCI13F (25, 50, 100,
and 200μM) were titrated in DNA binding reactions containing full-length heterotrimeric RPA. Binding to [32P]-ss 30-base 3Pc3 DNA was
assessed by EMSA as described in “Section 2.” (b) The same inhibitor concentrations were assessed in reactions measuring the binding of
DBD-A/B to a 30-mer substrate. (c) Analysis of control, MCI13E, and MCI13F inhibition of full length RPA. Average of three independent
experiments is shown with Standard Deviation as error bars. From this graph, IC50 were calculated. MCI13E had a calculated IC50 of
16.06 ±2.78μM, while MCI13F had a calculated IC50 of 10.11 ±1.0μM.8 Journal of Nucleic Acids
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Figure 5:Irreversibleinactivationoffull-lengthheterotrimericRPA
byMCI13E.IncubationofRPAwithMCI13E,dialysis,andrecovery
wereperformedasdescribedinthelegendtoFigure 3.DNAbinding
activity of the resulting protein was assessed by EMSA using a
5 -[32P]-ss 34-base DNA as described in “Section 2.” Lanes 1–4
predialysis, lanes 5 and 6 postdialysis.
EcSSB protein contains a single OB-fold, yet, forms a
homotetramer yielding a functional molecule containing
four OB-folds. The EcSSB protein also has been shown
to bind nucleic acid in the reverse polarity compared to
RPA [3]. On the other hand, the ssDNA-binding modes of
RPA and SpPot1 are more similar. With this in mind, our
demonstration that TDRL-505 displays inhibitory eﬀects on
both RPA and SpPot1(DBD) is not surprising. However, if
the aﬃnity of TDRL-505 was achieved through the common
structural elements of OB-folds, speciﬁcity of the inhibitor
w o u l db el e s sl i k e l y .T h eSpPot1(DBD) construct has been
biochemically characterized and, by analogy to hPot1, binds
ssDNA with the same 5  to 3  polarity as RPA p70 [30].
Structurally, residues 1–187 have been shown to contain
an OB-fold, and residues 188–389 have been postulated to
contain a second OB-fold, similar to the hPot1 protein [4]
and the RPA DBD-A/B construct. Although ssDNA-binding
interactions are mediated by similar structural elements
within each OB-fold domain in these proteins, the resulting
complexes diﬀer signiﬁcantly in the overall trajectory of
the ssDNA on the surface of the protein and the speciﬁc
hydrophobicstackinginteractionsofaromaticresiduesinthe
protein with the bases of the ssDNA (Figure 8). Thus, as each
of the proteins presents a distinct binding site for ssDNA, the
speciﬁcity of TDRL-505 seems to be limited relative to the
otherSMIstested(CheSS19andMCI13E/F)forinhibitionof
RPA as compared to other OB-fold-related proteins. Despite
the limited speciﬁcity, it would appear that TDRL-505 may
be speciﬁc to eukaryotic OB-fold-ssDNA interactions as it
fails to inhibit the EcSSB-ssDNA interaction.
The series of compounds based on a bicyclic framework
(MCI13E, MCI13F, and CheSS19) showed inhibition of full-
length heterotrimeric RPA. Interestingly the less reactive
derivatives containing a haloester (MCI13E and F) displayed
no inhibitory activity in DNA binding assays with puriﬁed
DBD-A/B while the more reactive tricyclic anhydride deriva-
tive,CheSS19,showedpotentinhibitory activityagainstboth
full-length RPA and the DBD-A/B construct. The mode of
RPA inhibition with the tricyclic anhydride and isoborneol
derivatives was found to be irreversible, consistent with the
reactive anhydride and haloester functional groups. None
of the isoborneol compounds were found to signiﬁcantly
inhibit the ssDNA binding activity of EcSSB suggesting
that this class of compounds is speciﬁc for RPA. Together
these data provide evidence suggestive of speciﬁc targeting
of diﬀerent functional domains of RPA that can be used
to exploit and interrogate their importance in the various
metabolic pathways in which RPA participates. Previous
data demonstrated that inhibition of RPA with SMIs results
in cell cycle arrest and sensitization to DNA-damaging
agents, cisplatin and etoposide [12]. These data suggest that
exploitation of this chemical genetic approach can ultimately
aid in the elucidation of the mechanism of RPA action in
criticalDNA metabolic pathwaysincluding DNAreplication,
recombination, and repair.
5. Conclusions
Small molecule inhibitors have proved to be invaluable in the
interrogation of biochemical pathways, protein activity, and
cellular function. While targeting macromolecular protein-
protein and protein-DNA interactions is somewhat more
complex than targeting an enzyme-substrate interaction,
recent work has yielded some success in this regard [12,
32–34]. In this paper, we provide evidence for TDRL-505
inhibition of RPA-DNA binding via an interaction with the
central OB-folds of RPA p70, DBD-A/B. This mechanism
of inhibition is likely to impact all DNA metabolic events
where RPA exerts its activity by high aﬃnity binding to
ssDNA. The demonstration that MCI13E and MCI13F do
not inhibit the DBD-A/B construct while showing potent
inhibition of the full-length RPA heterotrimer points to
other critical interactions between RPA and DNA that are
essential for its DNA binding activity. While the elucidation
of the speciﬁc sites of interaction of each SMI and RPA
remains, the irreversible inactivation of full-length RPA by
MCI13E provides a potential mechanism to identify the
speciﬁc amino acids being modiﬁed and hence determine
the subunit and potential DNA-binding domain targeted by
this SMI. The identiﬁcation of the speciﬁc site of TDRL-
505 interaction within DBD-A/B is being pursued via high-
resolution structural analyses, and together, will provide a
framework for the further elucidation of the mechanisms of
inhibition and how this impairment in DNA binding activity
inﬂuences cellular DNA metabolism.Journal of Nucleic Acids 9
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Figure 6: EcSSB protein-ssDNA interaction is not aﬀected by the RPA inhibitors. (a) Titration of TDRL-505 in EcSSB DNA-binding
reactions. TDRL-505 (0, 10, 20, 30, 40, 50, 75, and 100μM) was preincubated with EcSSB, and binding to a 30-base pair ssDNA was assessed
by EMSA as described in “Section 2.” (b) Analysis of TDRL-505 inhibition of EcSSB. The average of three independent experiments is
presented with SD. (c) CheSS19 titration in EcSSB DNA-binding reactions. CheSS19 (0, 25, 50, 100, and 200μM) was preincubated with
EcSSB, and binding reactions were carried out as in (a). (d) Analysis of CheSS19 inhibition of EcSSB. The average of three independent
experiments is presented with SD. (e) Titration of MCI13E and MCI13F in EcSSB DNA-binding reactions. Concentrations of MCI13E/F
used were 0, 25, 50, 100, and 200μM. (f) Analysis of MCI13E/F inhibition of EcSSB. The average of three independent experiments is
presented with SD. Data for MCI13E is shown as ﬁlled circles, and MCI13F is shown as open circles. In panels (a), (c), and (e), the “Free”
ssDNA is indicated with an arrow, and the “Bound” ssDNA is indicated by brackets. All reactions were performed in the same order and
manner as the RPA-binding reactions.10 Journal of Nucleic Acids
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Figure 7: TDRL-505 inhibits SpPot1(DBD) ssDNA binding. (a) Titration of TDRL-505 in ssDNA-binding reactions with SpPot1(DBD).
TDRL-505 was preincubated with SpPot1(DBD) (0, 25, 50, 100μM) prior to EMSA analysis of binding to the 15-mer oligonucleotide. “Free”
ssDNA is indicated with an arrow, and the “Bound” ssDNA is indicated by a bracket. (b) Analysis of TDRL-505 inhibition of SpPot1(DBD).
The average of three independent experiments is presented with SD.
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Figure 8: Comparison of the ssDNA-binding interface of OB-fold containing proteins. Proteins are shown as cartoon and ssDNA as stick
renderings. (a) Structure of the homotetramer of EcS S B( 1 E Y G ) ;D N Ai ss h o w ni ng o l d[ 31]. (b) Structure of the RPA DBD-A/B (1JMC);
DNA is shown in orange [27] (c) Structure of the human Pot1(DBD) (1XJV); DNA is shown in orange [4]. Each structure is shown in the
same orientation to highlight the diﬀerent ssDNA binding interfaces used by each of these proteins for their speciﬁc functions.
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